CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

https://doi.org/10.5281/zenodo.14238124

https://www.iajps.com/volumes/volume11-october-2024/64-issue-10-october-24/

Available online at: http://www.iajps.com *Research Article*

AN OVERVIEW OF GLOMERULONEPHRITIS

Rasha Khaled Sendy[1], Alhassan Mubarak Ali Alyami[2], Ghazy Radhy Al Hamad[3], Nahla Shaker Saati[4], Mohammed Abdulrahman Aljohani[5], Rawan Mohammed Hakami[6], Fairooz Othman Fadlelseed[7], Abdullah Matar Almutairi[8], Abdulaziz Saud Almordhi[8], Haya Fahad Alsuwailem[9], Huda Baqer Aljubarah[9], Ali Ahmed Alkhulif[9], Anwar Fahad Alkhamis[9], Hussain Ahmed Alaesh[10]

[1] King Fahad General Hospital – Jeddah – Saudi Arabia
[2] Prince Mansour Military Hospital – Taif – Saudi Arabia
[3] King Fahad Hospital – Hofuf – Saudi Arabia
[4] King Abdullah Medical City Complex – Jeddah – Saudi Arabia
[5] Al-Rayan Colleges - Madina - Saudi Arabia
[6] Ibn Sina National College - Jeddah - Saudi Arabia
[7] Alwajh General Hospital - Alwajh - Saudi Arabia
[8] Security Forces Hospital - Riyadh - Saudi Arabia
[9] King Abdulaziz Hospital - National Guard Affairs - Al Hasa - Saudi Arabia
[10] Al Jafer Hospital - Al Ahsa - Saudi Arabia

Abstract:

Background: *Glomerulonephritis (GN) encompasses various kidney conditions distinguished by the inflammation of glomeruli. Overlooking these health concerns adequately might cause serious health implications and has the chance to evolve into chronic kidney disease (CKD) or end-stage renal disease (ESRD). GN can be categorized by histopathological patterns, immunopathogenesis, or clinical presentation, offering insights into possible treatments.*

Objective: *an overview of the types, pathogenesis, diagnosis, and management of (GN).*

Methods: *a comprehensive review of (GN) and therapy. The PUBMED and Google Scholar search engines were the main databases used for the search process, with articles collected from 2001 to 2024.*

Conclusion: *(GN) is a complex, immune-mediated kidney disease with diverse clinical forms that demand precise diagnostic and therapeutic approaches. Advanced techniques such as histopathology and immunofluorescence are indispensable for accurate classification, enabling healthcare providers to implement targeted, patient-centered treatment strategies. Effective management, especially in conditions like IgA nephropathy and focal segmental glomerulosclerosis, integrates ACE inhibitors, ARBs, corticosteroids, and, in complex cases, immunosuppressive therapies to reduce inflammation and preserve kidney function. Patients with GN face significant risks, including the progression to chronic kidney disease (CKD) and end-stage renal disease (ESRD), as well as cardiovascular and electrolyte complications. Prompt intervention and tailored care, guided by KDIGO Clinical Practice Guidelines, are vital for improving patient outcomes, particularly in low- and middle-income countries where resources may be limited. By combining clinical, laboratory, and imaging assessments, and by continuing research into GN's immunopathology, healthcare providers can enhance long-term care strategies and effectively address the unique challenges posed by this multifaceted disease.*

Keywords: *Glomerulonephritis, Classification, Clinical Presentation, Management, Complications.*

Corresponding author:
Rasha Khaled Sendy *,
King Fahad General Hospital – Jeddah – Saudi Arabia

*Please cite this article in press Rasha Khaled Sendy et al., **An Overview Of Glomerulonephritis..**,Indo Am. J. P. Sci, 2024; 11 (10).*

INTRODUCTION:

The epidemiology of (GN) encompasses the study of its distribution, determinants, and the various forms it takes within populations. Notably, the understanding of GN is often limited in low- and middle-income countries (LMICs) due to inadequate nephropathology services and concerns regarding the safety of kidney biopsy procedures. Enhancing these services and ensuring access to specific therapies are crucial for improving outcomes in glomerular diseases in these regions (1). Within the diverse primary types of (GN), focal segmental glomerulosclerosis, commonly known as FSGS, is identified as the most regularly observed form, particularly in adult populations, characterized by the injury experienced by podocytes, specialized kidney cells, and this injury is of significant relevance to the overall pathogenesis of the condition. In addition, membraneous nephropathy (MN), in a substantial deviation from other kidney disorders, is highlighted as the primary and most often encountered reason for nephrotic syndrome in adults. This condition is distinctly defined by the buildup of immune complex deposits, which ultimately causes the thickening of the glomerular capillary wall, resulting in various clinical implications and management challenges (2). The elaborate pathophysiological aspects that define (GN) chiefly hinge upon the nuanced interplay of immune responses, which are fundamental in the causation of the majority of cases identified, irrespective of whether these are categorized as primary or secondary to underlying systemic disorders that may affect the patient. This assertion is strongly supported by the observable presence of glomerular deposits consisting of immunoglobulin and complement components. This phenomenon has been conclusively demonstrated through the advanced techniques of immunofluorescence microscopy, allowing for detailed visualization of these immunological markers within the renal architecture (3). In comparison to other health conditions, anti-glomerular basement membrane (GBM) antibodies are notably significant in around 5% of cases noted, since these antibodies are specifically responsible for triggering rapidly progressive (GN), a serious kidney issue that can also relate to pulmonary hemorrhage, especially in pathological scenarios like Goodpasture's syndrome, characterized by the involvement of both kidneys and lungs (4). Additionally, In (GN), the complicated pathophysiological aspects, especially concerning ANCA-associated vasculitis (AAV), reveal a complex interaction of immune responses that ultimately lead to serious kidney damage, showcasing the challenging dynamics of this condition. An elaborate inquiry into AAV exposes three crucial syndromes: granulomatosis about polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis linked to polyangiitis (EGPA), acknowledged for their influence in broadening the comprehension of necrotizing small vessel vasculitis that threatens glomerular function. Also, Wegener's granulomatosis is identified as a rare type of AAV, and its prominence is derived from its tight link to necrotizing and crescentic (GN), an ailment that is a definitive sign of serious and possibly irreversible kidney damage. This distinct medical ailment is marked by the existence of extravascular necrotizing granulomatous inflammation, which ultimately causes a considerable and often crippling reduction in renal performance, illustrating the severe character of the underlying pathophysiological dynamics. The occurrence of necrotizing extra capillary (GN) acts as a distinctive and highly indicative marker of antineutrophil cytoplasmic antibody-associated renal vasculitis, effectively emphasizing the considerable severity of the inflammatory response that is taking place within the renal tissues (5).

Classification of Glomerulonephritis

(GN), an illness identified by the inflammatory response in the glomeruli of the kidneys can be precisely sorted into several distinct categories determined mainly by the unique mechanisms responsible for damaging these critical kidney components. The fundamental classifications that are widely recognized include mechanisms such as direct antibody binding to glomerular components, immune complex deposition that triggers inflammatory

responses, and pauci-immune conditions that present with minimal detectable immune deposits. 1. **Direct Antibody Binding**: This particular category is notably illustrated by a condition known as anti-glomerular basement membrane disease, wherein antibodies attach themselves directly to the walls of the glomerular capillaries, resulting in considerable and often severe glomerular injury that can significantly impair kidney function (6). Besides, 2. **Immune Complex Deposition**: A notable and esteemed study that underscores this health issue is systemic lupus erythematosus, usually labeled as SLE, which is particularly acknowledged for the development and configuration of immune complexes within the complex arrangement of the glomeruli present in the kidneys. This complex and multifaceted medical condition is intricately linked with a plethora of diverse autoimmune processes that ultimately lead to significant glomerular inflammation and consequential damage, manifesting in a range of clinical symptoms and complications that affect the overall health of the individual. Moreover, 3. **Pauci-Immune Conditions**: This revelation encompasses multiple illnesses, especially Wegener's granulomatosis and polyarteritis nodosa, each demonstrating a notable scarcity of immune deposits in the vulnerable sites. A range of medical issues tends to be associated with the detection of anti-neutrophil cytoplasmic autoantibodies (ANCA), indicating a special and separate physiological mechanism that aids in harming the glomeruli, the critical elements in the kidneys that filter blood (6). Nevertheless, it is vital to recognize the various forms of (GN), with one example being diffuse endocapillary (GN), a condition particularly recognized for its erratic surge in cell reproduction within the capillaries, typically triggered by infections from pathogens such as group A β-hemolytic streptococci (7). In addition, The kidney issue defined as (GN) is predominantly segmented into two vital types: primary and secondary (GN). The type known as primary (GN) manifests independently and is not associated with other systemic diseases, frequently arising from inherent or intrinsic complications within the kidney itself. This unique classification comprises an extensive assortment of renal-specific ailments, which may eventually manifest in numerous clinical signs, such as the detection of blood in the urine (hematuria), high protein content in the urine (proteinuria), the slow development towards chronic kidney dysfunction, and, in the direst circumstances, can result in the critical ailment identified as end-stage renal disease (ESRD) (8). Also, Unlike primary (GN), which appears independently, secondary (GN) primarily surfaces due to a direct correlation with various systemic ailments or infections that impact the body entirely. This distinct kind of (GN) can be caused or provoked by an array of medical illnesses, including systemic lupus erythematosus (SLE), a grave autoimmune condition identified by the unusual buildup of immune complexes within the renal tissues, resulting in substantial glomerular harm and malfunction. Also, Highlighting the truth that diabetic nephropathy and hypertensive nephropathy are often significant contributors to secondary (GN) is essential, as diabetes along with chronic hypertension can cause severe renal damage, thereby affecting general kidney health and pushing forward kidney diseases essential (9). In addition, The conditions known as acute Glomerulonephritis and chronic Glomerulonephritis highlight two fundamentally unique forms of kidney inflammation, each with distinctive traits and notable impacts on the holistic health of the patient. When addressing acute Glomerulonephritis (AGN), patients frequently reveal symptoms quickly that can be unsettling, encompassing hematuria, which signifies blood detected in the urine, proteinuria, marked by an unusual concentration of proteins in urine, and edema, indicating fluid retention and swelling. Moreover, it could lead to elevated blood pressure or hypertension, alongside a significant reduction in urine output; this often triggers a swift and troubling decline in kidney function, presenting substantial risks to the person. The issue in focus can arise from numerous different underlying factors, which may involve an array of mechanisms, particularly those stemming from post-infectious events, and among these, acute post-streptococcal (GN) is distinctly acknowledged as a central and typical example often referenced in the realm of medicine. (10). On the other hand, The situation with chronic (GN) (CGN) is distinctly different from other diseases, being marked by an enduring and continuous inflammation that inflicts substantial harm on the intricate structures referred to as glomeruli, vital for the kidney's filtration process, leading to a slow but certain deterioration in kidney functionality over time (11).

Understanding (GN) deeply relies on histopathology, which features numerous diseases that are typically defined by inflammation and the damage caused to the glomeruli in the kidneys, the key filtering components that are vital for fluid balance and waste removal. By employing the meticulous and detailed microscopic examination of renal tissue samples, histopathology facilitates the precise identification and quantification of various tissue features and abnormalities, which is vital for the accurate clinical diagnosis and effective management of these complex kidney disorders (12). Besides, This extensive analysis holds the promise of

revealing the nuanced shifts that transpire within the tissues and cells impacted by (GN), making it easier to grasp the essential reasons that may be affecting the evolution of this disorder. Alongside the execution of comprehensive histopathological assessments, executing meticulous immunofluorescence investigations is also critically significant, as these studies are essential in proficiently differentiating among the various immunopathological processes that are involved in the scenario of glomerular damage. Additionally, Investigations and research performed in these studies are essential for the detection of anti-GBM antibodies, known to occur in roughly 5% of human (GN) cases, and these antibodies are notably connected to more acute and quickly worsening expressions of the condition, including situations like Goodpasture's syndrome that may cause serious health challenges. Nevertheless, The elaborate interaction between histopathological observations in tissue specimens and the results derived from immunofluorescence techniques yields a complete and sophisticated understanding of the disease mechanisms at play, which thus equips healthcare professionals to modify and enhance treatment options in a way that is effective and prioritizes the patient experience (4).

Clinical Presentation of Glomerulonephritis

(GN) reveals itself through a variety of clinical symptoms and indicators, which hold significant weight for both precise diagnosis and successful treatment of the condition. Among the main signs presented by those afflicted with this disorder is swelling, known in medical terminology as edema, which signifies the enlargement caused by fluid retention in various bodily tissues, and this symptom is regularly noted as a key aspect associated with (GN). Also, Hematuria, characterized by blood in the urine, is yet another important clinical signal that is intimately associated with (GN), denoting the possibility of damage or compromise to the glomeruli, the tiny filtering units in the kidneys that are vital for sustaining overall kidney function. Besides, Hematuria, which is medically defined as the occurrence of blood within the urine, stands out as another prominent and clinically significant indicator that is closely associated with (GN), and it serves to suggest potential injury or damage sustained by the delicate glomeruli within the kidneys. Furthermore, the occurrence of proteinuria, which signifies an irregular level of protein in the urine, acts as a pivotal marker of this unique condition, regularly indicating the complex and foundational renal disorders that might be influencing the individual's kidney capabilities (13). Moreover, Patients often find themselves facing the troubling condition of hypertension, a phenomenon that is commonly noted and frequently arises as a direct consequence of excessive fluid accumulation in the body, coupled with underlying renal dysfunction that impairs the kidneys' ability to filter and regulate bodily fluids effectively. Lastly, a considerable decrease in urine output reveals itself as another vital sign of declining kidney functionality, which reflects the impaired state of the renal system and serves a crucial role in shaping the entire clinical framework linked to (GN), a serious ailment impacting the kidneys (13).

Nevertheless, To diagnose (GN), it's generally essential to conduct a detailed and comprehensive review of the multiple symptoms that the patient displays, alongside a battery of lab assessments tailored to evaluate and highlight any discrepancies that could appear in the urine. There are circumstances where a kidney biopsy [figure 1] could be needed to affirm the diagnosis, along with determining the precise underlying factor contributing to the inflammation in the glomeruli (14).

Figure (1): Renal biopsy findings in patients with membranous glomerulonephritis (MGN) and antineutrophil cytoplasmic antibody-associated NCGN. (A) A glomerulus exhibits segmental fibrinoid necrosis, GBM rupture, and an early segmental cellular crescent. There is no evidence of glomerular basement membrane (GBM) spike formation in this patient with stage 1 MGN. (Jones methenamine silver). (B) Another glomerulus displays more extensive fibrinoid necrosis, multifocal GBM rupture, and a large cellular crescent. (Jones methenamine silver). (C) Immunofluorescence staining for IgG reveals granular global glomerular capillary wall positivity, typical of MGN. (D) Immunofluorescence staining for IgG reveals mild intensity and segmental capillary wall positivity in this patient with segmental MGN. (Magnification, ×400 in A-D). (E) Ultrastructural evaluation reveals global subepithelial electron-dense deposits, the majority of which lie adjacent to GBM spikes. The findings appear most consistent with stage 2 MGN. (Magnification, ×4,000) **(15).**



Additionally, (GN) represents a complicated medical issue that reveals numerous specific laboratory results, essential for not only confirming a correct diagnosis but also for efficiently handling the patient's total health and therapeutic plan. One major factor that medical professionals consistently observe is the levels of serum creatinine, which have shown a strong relationship with the intensity and development of glomerular illnesses, giving a crucial perspective on the patient's kidney performance. When serum creatinine is elevated, it showcases the level of renal impairment and is closely tied to glomerular inflammation, particularly in certain circumstances

like Acute Post-Streptococcal (GN) (PSGN), where these associations are highlighted even more (16).
Also, Imaging studies hold an essential and pivotal position in both the diagnosis and ongoing management of (GN), employing a diverse array of modalities that are specifically designed to thoroughly assess the intricate structure and functional capabilities of the kidneys. Being a widely acknowledged and often employed non-invasive procedure, ultrasound proves particularly useful in measuring kidney dimensions and spotting abnormalities linked to (GN), establishing it as an excellent primary imaging modality in diverse clinical contexts. Besides the perks offered by ultrasound, computed tomography (CT) imaging delivers elaborate and thorough cross-sectional pictures that are tremendously advantageous in the identification of (GN), as well as in uncovering numerous complications that could develop, like renal scarring or blockages, thus enriching the overall comprehension of the ailment. Furthermore, magnetic resonance imaging (MRI) is distinguished as a notably beneficial diagnostic tool, as it provides clear images of kidney tissues that effectively assist in the meticulous evaluation of glomerular conditions while reducing the risks commonly tied to ionizing radiation exposure (17). However, The unification of these assorted imaging methods not only facilitates a complete and extensive review of kidney health concerns but also markedly increases the potential for exact diagnosis and careful treatment formulation, thereby assuring that patients benefit from the finest care designed for their specific ailments. This varied tactic not only stresses the vital importance of imaging in the efficient clinical administration of kidney disorders but also makes certain that healthcare providers are ready to render well-informed decisions that are founded on extensive and meticulous details regarding both the anatomical configurations and functional processes of the kidneys.

Management of Glomerulonephritis

The effective management of (GN), and more specifically the subtype known as IgA nephropathy, is systematically directed by the KDIGO Clinical Practice Guidelines, which meticulously present a wide array of comprehensive recommendations that cover not only the various treatment protocols but also the essential monitoring strategies necessary for optimal patient care (18). Besides, Routine healthcare typically involves the use of angiotensin-converting enzyme inhibitors (ACEIs) paired with angiotensin II receptor blockers (ARBs), both of which are extensively recognized for their effective antiproteinuric effects and their noteworthy kidney protective benefits, as demonstrated in various clinical investigations. These medication types are important for easing proteinuria, a common and concerning sign related to (GN), and in this capacity, they greatly assist in preserving the overall health and function of the kidneys. Moreover, alongside the application of ACEIs and ARBs, corticosteroids are commonly included in the treatment strategy formulated for addressing this condition. Research findings reveal that steroids can substantially decrease protein in urine and mitigate renal impairment in individuals with IgA nephropathy, leading to improved clinical results and life quality (19). Additionally, In instances that are deemed to be more advanced or progressive, the approach taken by the management team may incorporate the use of immunosuppressive therapy, a treatment strategy that is specifically customized and finely tuned to align with the unique medical condition of each patient, as well as their particular responses to the initial treatments that have been administered (20). The treatment objectives for (GN) encompass a wide array of considerations and are particularly centered on the essential tasks of mitigating inflammation, addressing and managing the various symptoms that patients may experience, and ultimately preventing any further damage to the kidneys, which is crucial for maintaining overall health. An essential and pivotal component of the treatment regimen involves the significant task of reducing the levels of proteinuria, which is recognized as a vital marker for assessing kidney functionality as well as the general state of health for the individual. The implementation of effective management strategies is frequently designed with the intent to lower the concentrations of protein found in the urine, which in turn serves as a positive reflection of enhanced renal outcomes and holds the potential to contribute to improved long-term health prospects for those patients undergoing treatment (21). Also, Also, the extensive oversight of numerous immune-driven glomerular disorders, which importantly involves conditions like IgA nephropathy and ANCA-associated vasculitis, underlines the imperative value of not just reducing mortality statistics but also preserving and advancing ideal kidney functionality in those affected. As treatment strategies evolve and modify over time, there is a steadily increasing emphasis on the importance of patient-reported results alongside the proficient oversight of various comorbidities, which are now widely acknowledged as fundamental factors in accurately determining and assessing what signifies successful treatment within the context of (GN) (22).
Moreover, The handling of the challenging ailment identified as (GN) commonly incorporates medical methods that spotlight immunosuppressive therapies

such as Mycophenolate mofetil (MMF), glucocorticoids, cyclosporin, and rituximab, key ingredients in treatment plans. Mycophenolate mofetil's effectiveness in tackling different glomerular diseases, with lupus nephritis being the most notable, is established; it surpasses the basic role of delivering immunosuppressive therapy in the initial phases of the illness, also serving as a robust anti-fibrotic agent in chronic conditions, which underscores its extensive therapeutic options. Also, Utilizing glucocorticoids, typically paired with mycophenolate mofetil (MMF) in clinical practices, aspires to boost the probability of achieving positive therapeutic results, with these substances being regarded as highly powerful anti-inflammatory medications that have been employed for about forty years, emphasizing their continual relevance in contemporary healthcare. These powerful medications demonstrate remarkable efficacy in diminishing proteinuria, particularly in pathological conditions such as minimal change (GN), even though the precise mechanisms through which they exert their beneficial effects remain inadequately clarified and understood within the scientific community (21). In addition, the monoclonal antibody known as rituximab, specifically aimed at the CD20 antigen, has come forth as a notably optimistic therapeutic approach for patients enduring idiopathic membranous (GN), as it has evidenced marked declines in proteinuria levels when applied in combination with steroid therapy. This strategic combination of these pharmacological agents not only facilitates a more personalized approach to the treatment regimen but also effectively addresses the intricate complexities associated with (GN), ultimately leading to enhanced outcomes for patients undergoing this challenging condition (23).

Figure (2): Complications of Glomerulonephritis



Patients diagnosed with (GN) face the risk of numerous serious complications that can deeply alter their health and general wellness. Among the critical problems that can surface is glomerulosclerosis, noted for the development of scars in the glomeruli; such scarring can cause a gradual reduction in kidney performance as time goes by and could eventually progress to chronic kidney disease (CKD), which poses a major and lasting health risk (24). Also, AKI, short for acute kidney injury, signifies an additional serious and possibly fatal complication that commonly appears in those experiencing (GN), an ailment defined by the swelling of the kidney's filtering components. The manifestation of AKI can present itself as a sudden and often alarming decline in the overall function of the kidneys, which subsequently leads to a dangerous accumulation of waste products within the bloodstream, ultimately resulting in elevated levels of morbidity and mortality among affected patients. Moreover, The relationship between (AKI) with (CKD) apparently signals concerns, as the fast shift of AKI can significantly propel the initiation of CKD, raising the hazard of arriving at end-stage renal disease (ESRD), a critical health predicament that calls for intensified specialized medical exploration (25). Additionally, the emergence of nephrotic syndrome may follow (GN), which is specifically defined by increased proteinuria, decreased serum protein, and notable edema across the body. The occurrence of this syndrome can bring about a multitude of additional issues, which could involve various forms of infections along with the creation of blood clots, all of which work to exacerbate and undermine the patient's general health state (26). Also, Hypertension, usually called high blood pressure, is recognized as a common and worrisome complication that develops, particularly due to the damage endured by the kidneys which can greatly hinder the body's effectiveness in managing blood pressure levels, thus fostering a harmful and frequently unending loop where elevated blood pressure causes further detriment to the already affected kidneys. Should this negative trend go

unchecked, it can advance into significant cardiovascular ailments, posing a notable hazard for those afflicted with chronic kidney disease, since these individuals are at a heightened chance of undergoing severe episodes like heart attacks and strokes, largely attributed to overlapping risk factors that include, yet are not limited to, high blood pressure and diabetes (27). Besides, Imbalances in electrolytes, which represent crucial disruptions in the quantities of key minerals within the body, frequently occur in individuals diagnosed with (GN), a disorder marked by the inflammation of the kidney's filtration structures; this situation primarily arises because when kidney functionality is compromised, it can significantly upset the fragile equilibrium of these essential electrolytes, ultimately resulting in a series of severe complications that could present as perilous heart rhythm issues and crippling muscle fatigue (28).

Prognosis and Outcomes

The predictions and consequences linked with (GN) present a noteworthy extent of inconsistency that is deeply swayed by the distinct category of the condition at hand and the severity of its expression, which can greatly modify the total clinical overview. As an illustration, when looking into IgA nephropathy, it is noticeable that it has a striking five-year survival rate of 94%, a statistic that suggests a very promising prognosis when aligned with other forms of (GN) that might not demonstrate such bright results (29). In stark contrast to other conditions, focal glomerulosclerosis reveals a remarkably different scenario, characterized by a notably low survival rate of merely 22%, which serves as a clear indication of its dismal prognosis and the significant challenges it poses for affected individuals (30). In addition, The future perspective or prediction for persons identified with (GN) is shaped not just by the particular variety of illnesses affecting the kidneys but is also greatly influenced by the existence of multiple risk elements that could worsen the ailment. By way of example, essential measures such as the ratio of crescents observed in kidney biopsies, the prevalence of hypertension, together with the estimated glomerular filtration rate (GFR) taken during diagnosis, act as fundamental forecasters that can assist in evaluating the probability of moving toward end-stage kidney disease in those impacted. Yet, This suggests that although a portion of patients might exhibit a favorable response to the prescribed treatment protocols, there exists another segment of patients who could encounter substantial difficulties, particularly in instances where the disease is not effectively managed or controlled promptly. In summary, the enduring forecasts for individuals experiencing (GN) are greatly impacted by the immediate recognition of the disorder alongside the deployment of relevant and specialized treatment plans crafted to suit the individual circumstances of each patient. A large group of individuals may encounter different results regarding their kidney function preservation, although untreated cases could potentially evolve into chronic kidney disease or escalate to the more dire phase referred to as end-stage renal disease, which carries significant health dangers. Thus, grasping the unique type of (GN) and its associated risk elements is critically vital, as this insight is pivotal in predicting patient outcomes and guiding treatment choices effectively.

REFERENCES:

1. Ekrikpo U, Obiagwu P, Chika-Onu U, Yadla M, Karam S, Tannor EK, et al. Epidemiology and Outcomes of Glomerular Diseases in Low- and Middle-Income Countries. Seminars in Nephrology. 2022;42(5).
2. Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, et al. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). 2020;24:526-40.
3. Cole BR, Valdes AJ. Pathology and Pathophysiology of Proteinuric Glomerular Disease. In: Klahr S, editor. The Kidney and Body Fluids in Health and Disease. Boston, MA: Springer US; 1983. p. 399-438.
4. Wilson CB, Dixon FJ. Immunopathologic mechanisms of renal disease. Ricerca in clinica e in laboratorio. 1975;5(1):17-38.
5. Kronbichler A, Lee KH, Denicolo S, Choi D, Lee H, Ahn D, et al. Immunopathogenesis of ANCA-Associated Vasculitis. 2020;21(19):7319.
6. Falk RJ, Jennette JC. A Nephrological View of the Classification of Vasculitis. In: Gross WL, editor. ANCA-Associated Vasculitides: Immunological and Clinical Aspects. Boston, MA: Springer US; 1993. p. 197-208.
7. Risdon RA, Turner DR. Diffuse Endocapillary and Mesangial Proliferative (GN). Atlas of Renal Pathology. Dordrecht: Springer Netherlands; 1980. p. 43-6.
8. Ellison B, Cader R, Willcocks L. Advances in primary (GN). 2024;85(7):1-11.
9. Kim MJ, Kim SW. Differential Diagnosis of Secondary (GN). Korean J Med. 2013;84(1):19-27.
10. Elzouki AY. Poststreptococcal Acute (GN). In: Elzouki AY, Harfi HA, Nazer HM, Stapleton FB, Oh W, Whitley RJ, editors. Textbook of Clinical

Pediatrics. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012. p. 2743-8.
11. Скворцов ВВ, Тумаренко АВ, Малякин ГИ, Голиева ЭАJСвоп. Современные подходы к фармакотерапии хронического гломерулонефрита. 2020(8):36-45.
12. Sharma R, Sharma K, Bala M, editors. Analysis of Histopathological Images: An Overview. 2022 International Conference on Computing, Communication, Security and Intelligent Systems (IC3SIS); 2022 23-25 June 2022.
13. Bhuiyan ANMSI, Zahangir A, Khondaker Zahirul H, Md Mostafa Z, Md Z. A Clinical Profile and Immediate Outcome of Acute (GN) (AGN) in Hospitalized Children. American Journal of Pediatrics. 2020;6(4):448-54.
14. Sethi S, De Vriese AS, Fervenza FC. Acute (GN). The Lancet. 2022;399(10335):1646-63.
15. Said S, Valeri A, Stokes MB, Masani N, D'Agati V, Markowitz G. Membranous (GN) with ANCA-Associated Necrotizing and Crescentic (GN). Clinical Journal of the American Society of Nephrology : CJASN. 2009;4:299-308.
16. Ceaser R. Histopathological Study of Glomerular Disaese (in Patients with Significant Proteinuria): A Study of 50 Cases: Stanley Medical College, Chennai; 2007.
17. Buchanan CE. Development of MRI techniques for the assessment of chronic kidney disease: University of Nottingham; 2016.
18. Zarbock A, John S, Jörres A, Kindgen-Milles D. Neue KDIGO-Leitlinien zur akuten Nierenschädigung. Der Anaesthesist. 2014;63(7):578-88.
19. Amoroso L, De Sanctis L, Cappelli P, Di Vito R, Sirolli V, Bonomini MJGIdNOUDSIdN. Management of IgA nephropathy. 2011;28(6):622-32.
20. McIntyre C, Fluck R, Lambie SJCn. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment. 2001;56(3):193-8.
21. Grcevska L, Polenakovic MJP. Mycophenolate mofetil in the treatment of glomerular diseases. 2007;28(1):57-68.
22. Alberici F, Tedesco M, Popov T, Balcells-Oliver M, Mescia FJFiI. Treatment goals in ANCA-associated vasculitis: defining success in a new era. 2024;15:1409129.
23. Busch M, Gerth J, Ott U, Schip A, Haufe CC, Gröne H-J, et al. Behandlung der idiopathischen membranösen (GN). Medizinische Klinik. 2008;103(7):519-24.
24. Snively CS, Gutierrez CJAfp. Chronic kidney disease: prevention and treatment of common complications. 2004;70(10):1921-8.
25. Marik PE. Acute Kidney Injury. Evidence-Based Critical Care. Cham: Springer International Publishing; 2015. p. 653-68.
26. Niaudet P. Congenital Nephrotic Syndrome. In: Elzouki AY, Harfi HA, Nazer HM, Stapleton FB, Oh W, Whitley RJ, editors. Textbook of Clinical Pediatrics. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012. p. 2793-8.
27. Chemello C, Aguilera M, Garre MC, Hernández MAC. Pharmacogenetics and Pharmacogenomics of Chronic Kidney Disease Comorbidities and Kidney Transplantation. In: Barh D, Dhawan D, Ganguly NK, editors. Omics for Personalized Medicine. New Delhi: Springer India; 2013. p. 801-17.
28. Hauser GJ, Kulick AF. Electrolyte Disorders in the PICU. In: Wheeler DS, Wong HR, Shanley TP, editors. Pediatric Critical Care Medicine: Volume 3: Gastroenterological, Endocrine, Renal, Hematologic, Oncologic and Immune Systems. London: Springer London; 2014. p. 147-71.
29. Shilov E, Tareeva I, Ivanov A, Troepol'skaia O, Krasnova T, Varshavskiĭ V, et al. The course and prognosis of mesangioproliferative (GN). 2002;74(6):11-8.
30. Polenakovic MH, Grcevska L, Dzikova SJNDT. The incidence of biopsy-proven primary (GN) in the Republic of Macedonia—long-term follow-up. 2003;18(suppl_5):v26-v7.